In a patient with HR+HER2+ early breast cancer who is receiving adjuvant T-DM1 for residual disease, do you overlap endocrine therapy with T-DM1?  


Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution